Teva, Samsung Bioepis enter partnership for commercialization of EPYSQLI
Pharmaceutical Industries announced that the companies have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis’ biosimilar to Soliris in the United States ...
Hosted on MSN1mon
Samsung Biologics inks $668m manufacturing deal with European pharma
In July 2024, Samsung Bioepis received US Food and Drug Administration (FDA) approval for Epysqli (eculizumab-aagh), a biosimilar to AstraZeneca acquiree Alexion Pharmaceuticals’ Soliris ...
The Bakersfield Californian1d
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI®
Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH),atypical hemolytic uremic syndrome (aHUS)andgeneralized myasthenia gravis (gMG)in the U ...